Endometrial cancer
endometrial cancer
CONTRALATERAL BREAST CANCER, ENDOMETRIAL CANCER, EVENTS
In the five-year group, the incidence of endometrial cancer was increased compared with the two-year group, HR 1.65 (95% CI 1.12–2.42, p = 0.010), Incidence of endometrial cancer. Events after 2 versus 5 years of tamoxifen treatment.CI = confidence interval; HR = hazard ratio; SHR = subhazard ratio; TAM = tamoxifen.22 patients were diagnosed with contralateral breast cancer before the randomization. Furthermore, 7 patients in the treatment group of 2 years TAM and 18 patients in that of 5 years TAM were diagnosed with endometrial cancer before (the) randomization. These patients were excluded in this analysis.Incidence of endometrial cancer for patients randomized to two versus five years of tamoxifen.The risk to develop endometrial cancer tended to be higher among patients receiving 40 mg tamoxifen compared to those receiving 20 mg, HR 1.44 (95% CI 0.96–2.61, p = 0.079).